Structure Therapeutics Q2 net loss widens on higher R&D costs

Structure Therapeutics

06/08/2026 21:45

Overview
Biopharmaceutical firm's Q2 net loss widened as operating expenses rose on clinical trial costs
Company dosed first patients in Phase 3 aleniglipron trials for chronic weight management
Cash position of $1.3 bln expected to fund operations and clinical milestones through 2028

Outlook
Company expects cash reserves to fund operations and key clinical milestones through end of 2028
Topline 72-week aleniglipron ACCESS OLE data expected in Q3 2026
Company plans to initiate combination GLP-1 and amylin receptor agonist clinical trial in Q4 2026

Result Drivers
CLINICAL TRIAL COSTS - Co said higher R&D expenses were mainly due to increased clinical trial activity, preclinical research, and personnel costs
PIPELINE ADVANCEMENT - Initiation of Phase 3 aleniglipron trials and ongoing development of other candidates drove spending

Company press release: ID:nGNX6c2p9k

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$106.16 mln
 
Q2 Income From Operations
 
-$118.63 mln
 
Q2 Operating Expenses
 
$118.63 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Structure Therapeutics Inc. is $101.00, about 99.9% above its August 5 closing price of $50.53

Reuters Recommended Reads
Aug 5 - Eli Lilly beats Q2 revenue estimates, raises FY revenue outlook
Aug 4 - Novo Nordisk Q2 lifts FY guidance on stronger GLP-1 demand
Aug 6 - vTv Therapeutics Q2 net loss widens on higher trial costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)